Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid ther...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-10-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924018618 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127685234196480 |
|---|---|
| author | Jingyi Li Jicheng Lv Muh Goet Wong Sufang Shi Jincan Zan Helen Monaghan Vlado Perkovic Hong Zhang Hong Zhang Vlado Perkovic Rajiv Agarwal Sean Barbour Daniel Cattran Alan Cass Tak Mao Chan John Feehally Richard Glassock Michelle A. Hladunewich Lai Seong Hooi Meg J. Jardine Vivekanand Jha David W. Johnson Adeera Levin Zhi-Hong Liu Jicheng Lv Helen Monaghan Heather Reich Giuseppe Remuzzi David C. Wheeler Muh Geot Wong Mark Woodward Yangfeng Wu Minghui Zhao |
| author_facet | Jingyi Li Jicheng Lv Muh Goet Wong Sufang Shi Jincan Zan Helen Monaghan Vlado Perkovic Hong Zhang Hong Zhang Vlado Perkovic Rajiv Agarwal Sean Barbour Daniel Cattran Alan Cass Tak Mao Chan John Feehally Richard Glassock Michelle A. Hladunewich Lai Seong Hooi Meg J. Jardine Vivekanand Jha David W. Johnson Adeera Levin Zhi-Hong Liu Jicheng Lv Helen Monaghan Heather Reich Giuseppe Remuzzi David C. Wheeler Muh Geot Wong Mark Woodward Yangfeng Wu Minghui Zhao |
| author_sort | Jingyi Li |
| collection | DOAJ |
| description | Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid therapy. Previous studies suggest glomerular macrophage infiltration is associated with response to immunosuppressive therapy in IgAN and urinary soluble CD163 ([u-sCD163], a marker of alternatively activated macrophages [M2]c macrophage) is correlated with clinical remission in vasculitis. This study aims to investigate the association between u-sCD163 and response of steroids therapy in IgAN. Methods: We measured u-sCD163 in patients from a large IgAN cohort and Chinese participants of the TESTING trial. The correlation of baseline or serial u-sCD163 and their response of corticosteroids therapy or kidney outcomes were investigated. Results: In cross-sectional analysis, u-sCD163 levels correlated with kidney macrophage infiltration, especially in crescentic areas, and with active lesions. Subgroup analysis of the TESTING cohort showed higher levels u-sCD163 were associated with greater benefits from corticosteroids therapy in proteinuria remission (odds ratio, 35.56 [95% confidence interval, CI: 7.62–292.34] vs. 3.94 [95% CI: 1.39–12.93], P for interaction: 0.036). Corticosteroids therapy significantly reduced u-sCD163 levels at 6 months compared to placebo group (79% [interquartile range: 58%–91%] vs. 37% [−11% to 58%], P <0.001). There was no difference in the suppressive effects on u-sCD163 by either dosage of corticosteroids (full and reduced-dose). The suppression of u-sCD163 was significantly associated with a reduced risk of kidney progression events (adjusted hazard ratio: 0.52, 95% CI: 0.30–0.93, P = 0.027). Conclusion: u-sCD163 is a reliable noninvasive biomarker associated with active pathological lesions in IgAN and can guide glucocorticoid therapy. |
| format | Article |
| id | doaj-art-7f9f3a004a3e4c5bbb24ec6c56568703 |
| institution | OA Journals |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-7f9f3a004a3e4c5bbb24ec6c565687032025-08-20T02:33:36ZengElsevierKidney International Reports2468-02492024-10-019103016302610.1016/j.ekir.2024.07.031Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA NephropathyJingyi Li0Jicheng Lv1Muh Goet Wong2Sufang Shi3Jincan Zan4Helen Monaghan5Vlado Perkovic6Hong Zhang7Hong ZhangVlado PerkovicRajiv AgarwalSean BarbourDaniel CattranAlan CassTak Mao ChanJohn FeehallyRichard GlassockMichelle A. HladunewichLai Seong HooiMeg J. JardineVivekanand JhaDavid W. JohnsonAdeera LevinZhi-Hong LiuJicheng LvHelen MonaghanHeather ReichGiuseppe RemuzziDavid C. WheelerMuh Geot WongMark WoodwardYangfeng WuMinghui ZhaoRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China; Correspondence: Jicheng Lv, Renal Division, Department of Medicine, Peking University First Hospital, Xishiku Street No. 8, Xicheng District, Beijing 100034, China.The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Renal Medicine, Concord Repatriation General Hospital, Concord, New South Wales, AustraliaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, ChinaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, ChinaThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, AustraliaThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, AustraliaRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, ChinaIntroduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid therapy. Previous studies suggest glomerular macrophage infiltration is associated with response to immunosuppressive therapy in IgAN and urinary soluble CD163 ([u-sCD163], a marker of alternatively activated macrophages [M2]c macrophage) is correlated with clinical remission in vasculitis. This study aims to investigate the association between u-sCD163 and response of steroids therapy in IgAN. Methods: We measured u-sCD163 in patients from a large IgAN cohort and Chinese participants of the TESTING trial. The correlation of baseline or serial u-sCD163 and their response of corticosteroids therapy or kidney outcomes were investigated. Results: In cross-sectional analysis, u-sCD163 levels correlated with kidney macrophage infiltration, especially in crescentic areas, and with active lesions. Subgroup analysis of the TESTING cohort showed higher levels u-sCD163 were associated with greater benefits from corticosteroids therapy in proteinuria remission (odds ratio, 35.56 [95% confidence interval, CI: 7.62–292.34] vs. 3.94 [95% CI: 1.39–12.93], P for interaction: 0.036). Corticosteroids therapy significantly reduced u-sCD163 levels at 6 months compared to placebo group (79% [interquartile range: 58%–91%] vs. 37% [−11% to 58%], P <0.001). There was no difference in the suppressive effects on u-sCD163 by either dosage of corticosteroids (full and reduced-dose). The suppression of u-sCD163 was significantly associated with a reduced risk of kidney progression events (adjusted hazard ratio: 0.52, 95% CI: 0.30–0.93, P = 0.027). Conclusion: u-sCD163 is a reliable noninvasive biomarker associated with active pathological lesions in IgAN and can guide glucocorticoid therapy.http://www.sciencedirect.com/science/article/pii/S2468024924018618crescentic lesionsIgA nephropathytreatmentu-sCD163 |
| spellingShingle | Jingyi Li Jicheng Lv Muh Goet Wong Sufang Shi Jincan Zan Helen Monaghan Vlado Perkovic Hong Zhang Hong Zhang Vlado Perkovic Rajiv Agarwal Sean Barbour Daniel Cattran Alan Cass Tak Mao Chan John Feehally Richard Glassock Michelle A. Hladunewich Lai Seong Hooi Meg J. Jardine Vivekanand Jha David W. Johnson Adeera Levin Zhi-Hong Liu Jicheng Lv Helen Monaghan Heather Reich Giuseppe Remuzzi David C. Wheeler Muh Geot Wong Mark Woodward Yangfeng Wu Minghui Zhao Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy Kidney International Reports crescentic lesions IgA nephropathy treatment u-sCD163 |
| title | Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy |
| title_full | Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy |
| title_fullStr | Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy |
| title_full_unstemmed | Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy |
| title_short | Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy |
| title_sort | correlation of urinary soluble cd163 levels with disease activity and treatment response in iga nephropathy |
| topic | crescentic lesions IgA nephropathy treatment u-sCD163 |
| url | http://www.sciencedirect.com/science/article/pii/S2468024924018618 |
| work_keys_str_mv | AT jingyili correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT jichenglv correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT muhgoetwong correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT sufangshi correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT jincanzan correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT helenmonaghan correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT vladoperkovic correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT hongzhang correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT hongzhang correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT vladoperkovic correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT rajivagarwal correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT seanbarbour correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT danielcattran correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT alancass correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT takmaochan correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT johnfeehally correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT richardglassock correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT michelleahladunewich correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT laiseonghooi correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT megjjardine correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT vivekanandjha correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT davidwjohnson correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT adeeralevin correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT zhihongliu correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT jichenglv correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT helenmonaghan correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT heatherreich correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT giusepperemuzzi correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT davidcwheeler correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT muhgeotwong correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT markwoodward correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT yangfengwu correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy AT minghuizhao correlationofurinarysolublecd163levelswithdiseaseactivityandtreatmentresponseiniganephropathy |